Publications
5491 Results
- Journal / Conference
- American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #337
- Year
- 2021
- Research Committee(s)
- Leukemia
- Study Number(s)
- C10403
Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data
- Journal / Conference
- American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), poster, #3728
- Year
- 2021
- Research Committee(s)
- Leukemia
A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
- Journal / Conference
- American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #639
- Year
- 2021
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/A041202
Long term results of A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab chemoimmunotherapy
- Journal / Conference
- American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), poster presentation, #1423
- Year
- 2021
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0014, S0313, S1001
Extranodal presentation in limited stage DLBCL as a prognostic marker in three sequential SWOG trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)
- Journal / Conference
- American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #523
- Year
- 2021
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/A051701
Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance 051701
- Journal / Conference
- American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #220
- Year
- 2021
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0432, S0703, S1612
Prediction Of Early Mortality With Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients From MRC/NCRI and SWOG
- Journal / Conference
- Society for Immunotherapy of Cancer’s (SITC) Annual Meeting (Nov 10-14, 2021, Washington, DC), poster
- Year
- 2021
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1609
Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known
- Journal / Conference
- Society for Immunotherapy of Cancer’s (SITC) Annual Meeting (Nov 10-14, 2021, Washington, DC), poster
- Year
- 2021
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1609
Females with high-risk melanoma are more likely to benefit from CTLA4 immune checkpoint inhibition with associated evidence of enhanced immune activation within the TME and the circulation
- Journal / Conference
- American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), TIPs poster, #3565
- Year
- 2021
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1918
S1918: A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
- Journal / Conference
- American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #453
- Year
- 2021
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/9177